Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: BFHammer who wrote (3351)	12/12/2014 10:25:30 AM
From: donpat	Read Replies (1) \| Respond to of 12871

Who figured the ebola attachment was NPC1? I believe USAMRIID did some papers on that. I'll check later - I've got to go to Horton's for BK (breakfast) now!

To: BFHammer who wrote (3351)	12/12/2014 10:26:30 AM
From: AnotherVoice	Respond to of 12871

this is a copy of an email I sent my very good friends and relatives. As the overall market changes to reflect the price of oil many things will change. Because oil is such a large part of transportation costs?, farming, energy production, and consumer mobility prices will decline. Prices are sticky on the way down so a slow decline except at the pump will be slow to see. Investors will be looking for a place to put the money they are saving. With some cash NNVC will seem a very attractive option in their desire for an unbelievable gain. All that is need is for NNVC's PR department to get the word out as to how well the Labs found our cides to work. Simple statements from the company are not enough for the doubting Thomas's of the investment world. And a price above $5.00 is need to allow some of the big funds to participate. IMHO

To: BFHammer who wrote (3351)	12/12/2014 1:31:23 PM
From: HardToFind	Respond to of 12871

> looking forward, is there a biotech that specializes in diagnosing what the contact point of a virus would be? ...Is there a public company that we could look to partner with that has this specialty? From my catbird seat, that would be a crazy combo. Really interesting concept. I think NNVC goes around and works with a wide variety of basic researchers on particular viruses. I wonder how difficult it is to determine, and if discovery of points of contact would have any IP protection. If there's no barrier to entry, then the IP business model is suspect...I wonder how that works. Maybe one could do such research for hire, develop a lab qualified to handle deadly viruses, and specialize in both applying for research money as well as looking for pharma clients. In truth, in cases like Ebola and HIV, you want to be working with somebody that knows a lot about the virus beyond just the points of contact. EbolaCide I was less effective than expected not because we got the points of contact wrong, but because of other mechanisms. So now we're on EbolaCide II. We're also on HIV-Cide II (or more). It seems one might want to hire out specialists on particular viruses to companies for consulting gigs. If they are in academia, call it a sabbatical. Specialize in being their agents, sort of like sports agents. Get them a generous salary and a piece of the equity upside. The challenge is that you also want them to do your testing, and write the findings for the journals. Academic folks get a long way in their careers by becoming a leading (published) expert in their areas of interest. And along the way you don't want to create a conflict of interest. Sounds tricky, but there seems like a potential for a serious business if one is willing to map out the business path.